News & Updates

A uniform cardiac troponin threshold to identify myocardial infarction (MI) risk demonstrates safety and efficacy in both male and female patients, reports a study.

Late gadolinium enhancement (LGE) with septal location is significantly associated with major arrhythmic events among patients with dilated cardiomyopathy (DCM) and nondilated left ventricular (LV) cardiomyopathy (NDLVC), suggests a recent study.

Dropping aspirin for ticagrelor monotherapy 1 month after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is as good as dual antiplatelet therapy (DAPT) in the ULTIMATE-DAPT* trial presented at ACC.24.

Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.

The weight loss and heart failure (HF) benefits of semaglutide extend to patients with obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) in the STEP-HFpEF DM trial, fuelling speculation that semaglutide may have cardiovascular effects beyond weight loss.